

# Complete Genome Sequence of *Achromobacter xylosoxidans* MN001, a Cystic Fibrosis Airway Isolate

Jonathan P. Badalamenti,<sup>a</sup> Ryan C. Hunter<sup>b</sup>

BioTechnology Institute, University of Minnesota, St. Paul, Minnesota, USA<sup>a</sup>; Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA<sup>b</sup>

**The genome of *Achromobacter xylosoxidans* MN001, a strain isolated from sputum derived from an adult cystic fibrosis patient, was sequenced using combined single-molecule real-time and Illumina sequencing. Assembly of the complete genome resulted in a 5,876,039-bp chromosome, representing the smallest *A. xylosoxidans* genome sequenced to date.**

Received 12 July 2015 Accepted 14 July 2015 Published 20 August 2015

**Citation** Badalamenti JP, Hunter RC. 2015. Complete genome sequence of *Achromobacter xylosoxidans* MN001, a cystic fibrosis airway isolate. *Genome Announc* 3(4):e00947-15. doi:10.1128/genomeA.00947-15.

**Copyright** © 2015 Badalamenti and Hunter. This is an open-access article distributed under the terms of the [Creative Commons Attribution 3.0 Unported license](https://creativecommons.org/licenses/by/3.0/).

Address correspondence to Ryan C. Hunter, [rchunter@umn.edu](mailto:rchunter@umn.edu).

*Achromobacter xylosoxidans* is an aerobic Gram-negative bacterium that is widely distributed throughout freshwater and soil environments. This bacterium is also an opportunistic human pathogen of immunocompromised hosts and is commonly associated with a range of respiratory infections. In individuals with cystic fibrosis (CF), *A. xylosoxidans* has seen an increase in prevalence, with some treatment centers reporting positive culture rates as high as 17.6% (1). Culture-independent 16S rRNA gene studies suggest that this frequency might be even higher. Despite its association with chronic lung infections and poor pulmonary function scores (2), the impact of *A. xylosoxidans* on CF disease progression is not entirely clear. This uncertainty, in addition to the bacterium's multidrug resistance (3), robust biofilm formation (4), and transmissibility (5), warrants further study of the molecular basis for its phenotypes. Here, we report the complete genome sequence of *A. xylosoxidans* MN001—a multidrug-resistant isolate recovered from multiple patients at the University of Minnesota Cystic Fibrosis Center (institutional review board approval 1401M47262).

Genomic DNA (gDNA) was isolated from MN001 using the Wizard purification kit (Promega) and sequenced using single-molecule real-time (SMRT) and Illumina technologies. SMRT libraries were constructed according to Pacific Biosciences protocols with a 20-kb insert size. Following ligation of SMRTbell adapters, sheared gDNA was size selected with a 4-kb cutoff using Blue Pippin electrophoresis (Sage Science) to generate a greater fraction of long reads capable of resolving repeat sequencing in the *A. xylosoxidans* genome. Sequencing was performed using the PacBio RS II platform. Subread filtering from 2 SMRTcells captured with a 240-min movie and P6-C4 chemistry yielded 592 Mbp of sequence reads with an average read length of 11,520 bp ( $N_{50}$ , 16,106 bp). Assembly was performed using the Hierarchical Genome Assembly Process (HGAP) version 3 (6) in SMRT Analysis version 2.2 hosted on the University of Minnesota supercomputer. Remaining indels were removed with three successive passes through Quiver to achieve a final consensus accuracy of >99.9997% (QV 56) at 100× coverage. This assembly consisted of one circular contig representing a 5,876,039-bp chromosome. Illumina libraries were analyzed using

MiSeq with 250-bp paired-end sequences, yielding ~2.5 million reads. Reads were mapped onto the SMRT-derived contig using breseq version 0.24rc6 (7), and the 10 indels remaining after polishing were corrected using Pilon version 1.10 (8), yielding essentially perfect final per-base accuracy. The MN001 genome was annotated with Prokka version 1.11 (9) using *A. xylosoxidans* NH44874-1996 (4) as the reference genome.

At 5.8 Mbp, the MN001 genome is remarkably smaller than the seven *A. xylosoxidans* genomes published to date. The G+C content is 67.72%, which is consistent with previously sequenced strains. A total of 5,328 genes, including 10 rRNA (3 16S, 3 23S, 4 5S) and 67 tRNA genes, were annotated. Function was assigned for 4,333 of 5,251 predicted coding sequences (>82%). Detailed analyses of the MN001 genome, including comparative studies with other *A. xylosoxidans* strains are in progress.

**Nucleotide sequence accession numbers.** The assembly and annotation have been deposited in GenBank under the accession number [CP012046](https://ncbi.nlm.nih.gov/nucl/CP012046). PacBio and Illumina reads have been deposited to the NCBI Sequence Read Archive under BioProject number [PRJNA288995](https://ncbi.nlm.nih.gov/bioproject/PRJNA288995).

## ACKNOWLEDGMENTS

This work was supported by the University of Minnesota Medical School.

We thank Karl Oles (Mayo Clinic Bioinformatics Core) for performing PacBio library preparation and sequencing, and Kevin Silverstein, John Vestrum, and the staff at the UMN MSI for their efforts in installing and supporting PacBio SMRT Analysis. We also thank the patients and caregivers at the UMN Adult CF Treatment Center for their support of this research.

## REFERENCES

- Lambiase A, Catania MR, del Pezzo M, Rossano F, Terlizzi V, Sepe A, Raia V. 2011. *Achromobacter xylosoxidans* respiratory tract infection in cystic fibrosis patients. *Eur J Clin Microbiol Infect Dis* 30:973–980. [http://dx.doi.org/10.1007/s10096-011-1182-5](https://doi.org/10.1007/s10096-011-1182-5).
- Hansen CR, Pressler T, Høiby N, Gormsen M. 2006. Chronic infection with *Achromobacter xylosoxidans* in cystic fibrosis patients; a retrospective case control study. *J Cyst Fibros* 5:245–251. [http://dx.doi.org/10.1016/j.jcf.2006.04.002](https://doi.org/10.1016/j.jcf.2006.04.002).

3. Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z, Lai L, Whittier S. 2001. Identification and antimicrobial susceptibility of *Alcaligenes xylosoxidans* isolated from patients with cystic fibrosis. *J Clin Microbiol* 39:3942–3945. <http://dx.doi.org/10.1128/JCM.39.11.3942-3945.2001>.
4. Jakobsen TH, Hansen MA, Jensen PØ, Hansen L, Riber L, Cockburn A, Kolpen M, Hansen CR, Ridderberg W, Eickhardt S, Hansen M, Kerpedjiev P, Alhede M, Qvortrup K, Burmølle M, Moser C, Kühl M, Ciofu O, Givskov M, Sørensen SJ, Hoiby N, Bjørnsholt T. 2013. Complete genome sequence of the cystic fibrosis pathogen *Achromobacter xylosoxidans* NH44784-1996 complies with important pathogenic phenotypes. *PLoS One* 8:e68484. <http://dx.doi.org/10.1371/journal.pone.0068484>.
5. Van Daele S, Verhelst R, Claeys G, Verschraegen G, Franckx H, Van Simaey L, de Ganck C, De Baets F, Vaneechoutte M. 2005. Shared genotypes of *Achromobacter xylosoxidans* strains isolated from patients at a cystic fibrosis rehabilitation center. *J Clin Microbiol* 43:2998–3002. <http://dx.doi.org/10.1128/JCM.43.6.2998-3002.2005>.
6. Chin C-S, Alexander DH, Marks P, Klammer AA, Drake J, Heiner C, Clum A, Copeland A, Huddleston J, Eichler EE, Turner SW, Korlach J. 2013. Nonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data. *Nat Methods* 10:563–569. <http://dx.doi.org/10.1038/nmeth.2474>.
7. Barrick JE, Colburn G, Deatherage DE, Traverse CC, Strand MD, Borges JJ, Knoester DB, Reba A, Meyer AG. 2014. Identifying structural variation in haploid microbial genomes from short-read resequencing data using breseq. *BMC Genomics* 15:1039. <http://dx.doi.org/10.1186/1471-2164-15-1039>.
8. Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakthikumar S, Cuomo CA, Zeng Q, Wortman J, Young SK, Earl AM. 2014. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. *PLoS One* 9:e112963. <http://dx.doi.org/10.1371/journal.pone.0112963>.
9. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30:2068–2069. <http://dx.doi.org/10.1093/bioinformatics/btu153>.